This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of the TrialNet consortium is to develop clinical trials of treatments that protect pancreatic -cell function, in individuals who are at risk for developing T1D or who have newly diagnosed T1D. Optimal design and completion of these trials depends upon knowledge of the natural history of T1D and effective strategies to recruit subjects. The goals of the TrialNet Natural History Study of the Development of Type 1 Diabetes are to gain information about the natural history and pathogenesis of T1D and to facilitate the recruitment and assessment of individuals who might qualify for T1D prevention trials. The TrialNet Natural History Study of the Development of T1D is divided into three phases: Phase 1 Screening, Phase 2 Baseline Risk Assessment, and Phase 3 Follow-Up Risk Assessment.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR001032-31
Application #
7380677
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-04-01
Project End
2007-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
31
Fiscal Year
2006
Total Cost
$72,393
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Chung, Chen-Chih; Pimentel Maldonado, Daniela A; Jor'dan, Azizah J et al. (2018) Lower cerebral vasoreactivity as a predictor of gait speed decline in type 2 diabetes mellitus. J Neurol 265:2267-2276
Kline, Emily R; Seidman, Larry J; Cornblatt, Barbara A et al. (2018) Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophr Res 192:357-363
Simpson, Norah S; Scott-Sutherland, Jennifer; Gautam, Shiva et al. (2018) Chronic exposure to insufficient sleep alters processes of pain habituation and sensitization. Pain 159:33-40
Dai, Weiying; Duan, Wenna; Alfaro, Freddy J et al. (2017) The resting perfusion pattern associates with functional decline in type 2 diabetes. Neurobiol Aging 60:192-202
Brosnahan, Godela M; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev 13:109-120
Torres, Vicente E; Abebe, Kaleab Z; Schrier, Robert W et al. (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91:493-500
Irazabal, María V; Abebe, Kaleab Z; Bae, Kyongtae Ty et al. (2017) Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant 32:1857-1865
Seidman, Larry J; Shapiro, Daniel I; Stone, William S et al. (2016) Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study. JAMA Psychiatry 73:1239-1248
Thermenos, Heidi W; Juelich, Richard J; DiChiara, Samantha R et al. (2016) Hyperactivity of caudate, parahippocampal, and prefrontal regions during working memory in never-medicated persons at clinical high-risk for psychosis. Schizophr Res 173:1-12

Showing the most recent 10 out of 642 publications